Mylan, like the rest of its generics peers, is suffering in the U.S. thanks to stepped-up pricing pressure. But it’s hoping a new biosimilar can eventually help its stateside sales.Original Article
Mylan trumpets Botox biosimilar deal ahead of ‘decent’ Q4 earnings
